Jeff Yass’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.4K Buy
1,657
+1,180
+247% +$21.8K ﹤0.01% 13053
2026
Q1
$7.72K Buy
477
+117
+33% +$2.58K ﹤0.01% 12960
2025
Q4
$8.53K Sell
360
-247
-41% -$7.28K ﹤0.01% 12069
2025
Q3
$18.9K Sell
607
-100
-14% -$3.15K ﹤0.01% 12059
2025
Q2
$14K Buy
+707
New +$14.2K ﹤0.01% 12377
2022
Q4
Sell
-67
Closed -$11K 13688
2022
Q3
$11K Buy
+67
New +$13K ﹤0.01% 12764
2022
Q1
Sell
-85
Closed -$18K 13980
2021
Q4
$18K Sell
85
-814
-91% -$231K ﹤0.01% 12847
2021
Q3
$291K Buy
899
+59
+7% +$20.8K ﹤0.01% 10668
2021
Q2
$370K Sell
840
-27
-3% -$13.5K ﹤0.01% 10321
2021
Q1
$489K Buy
867
+322
+59% +$232K ﹤0.01% 9519
2020
Q4
$311K Buy
545
+308
+130% +$153K ﹤0.01% 9182
2020
Q3
$71K Sell
237
-1,447
-86% -$502K ﹤0.01% 10085
2020
Q2
$551K Buy
+1,684
New +$385K ﹤0.01% 7166
2015
Q3
Sell
-105
Closed -$285K 10206
2015
Q2
$285K Buy
+105
New +$273K ﹤0.01% 8620
2014
Q4
Sell
-75
Closed -$206K 10105
2014
Q3
$206K Buy
75
+2
+3% +$6.5K ﹤0.01% 8630
2014
Q2
$251K Buy
+73
New +$260K ﹤0.01% 8681
2013
Q4
Sell
-72
Closed -$235K 9342
2013
Q3
$235K Buy
+72
New +$211K ﹤0.01% 7550

Other funds holding TRIB

Jeff Yass's TRIB Position: Q2 2026 in Review

Jeff Yass opened a new position in Trinity Biotech (TRIB) in Q2 2026: 895 shares worth $10.4K. The stake represents ﹤0.01% of the portfolio and ranks #13124 among its holdings. This is a return to the name: Jeff Yass previously reported a position in TRIB as recently as Q4 2025.

Jeff Yass first reported a position in TRIB in Q3 2013 and has held it in 25 quarters since. The position peaked at $1.02M in Q2 2014. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2026.

  • Jeff Yass held 895 shares of Trinity Biotech worth $10.4K as of Q2 2026.
  • Trinity Biotech was a new Jeff Yass position in Q2 2026.
  • Trinity Biotech made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #13124 holding.
  • Jeff Yass first reported a position in Trinity Biotech in Q3 2013 and has held it in 25 quarters since.
  • Jeff Yass's Trinity Biotech position peaked at $1.02M in Q2 2014.
  • 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.